TherapeuticsMD (TXMD) Gross Profit (2011 - 2023)

TherapeuticsMD (TXMD) has reported Gross Profit for 13 consecutive years, with $502000.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Gross Profit fell 99.27% year-over-year to $502000.0; the trailing twelve-month figure through Dec 2023 stood at $1.3 million (down 98.43% YoY), and the FY2023 full-year result was $1.3 million, down 98.1% from the prior year.
• Gross Profit rose to $502000.0 in Q4 2023 per TXMD's latest filing, from -$53000.0 in the prior quarter.
• Across five years, Gross Profit topped out at $68.6 million in Q4 2022 and bottomed at -$53000.0 in Q3 2023.
• Historically, Gross Profit has averaged $13.6 million across 5 years, with a median of $13.5 million in 2019.
• The sharpest annual moves came in 2019 and 2023: Gross Profit soared 702.7% in 2019, then tumbled 99.27% in 2023.
• Over 5 years, Gross Profit stood at $13.0 million in 2019, then soared by 30.52% to $17.0 million in 2020, then retreated by 17.98% to $13.9 million in 2021, then jumped by 391.83% to $68.6 million in 2022, then sank by 99.27% to $502000.0 in 2023.
• According to Business Quant data, Gross Profit over the past three periods registered $502000.0, -$53000.0, and $437000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.